In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Overstock.com, Inc.
(NASDAQ:OSTK), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN),
Molecular Templates Inc. (NASDAQ:MTEM), The Ensign Group, Inc.
(NASDAQ:ENSG), Limoneira Co (NASDAQ:LMNR), and Primo Water
Corporation (NASDAQ:PRMW), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified
analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
OSTK DOWNLOAD:
http://Capital-Review.com/register/?so=OSTK REGN DOWNLOAD:
http://Capital-Review.com/register/?so=REGN MTEM DOWNLOAD:
http://Capital-Review.com/register/?so=MTEM ENSG DOWNLOAD:
http://Capital-Review.com/register/?so=ENSG LMNR DOWNLOAD:
http://Capital-Review.com/register/?so=LMNR PRMW DOWNLOAD:
http://Capital-Review.com/register/?so=PRMW
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine
Overstock.com, Inc. (NASDAQ:OSTK), Regeneron Pharmaceuticals, Inc.
(NASDAQ:REGN), Molecular Templates Inc. (NASDAQ:MTEM), The Ensign
Group, Inc. (NASDAQ:ENSG), Limoneira Co (NASDAQ:LMNR), and Primo
Water Corporation (NASDAQ:PRMW) on a fundamental level and outlines
the overall demand for their products and services in addition to
an in-depth review of the business strategy, management discussion,
and overall direction going forward. Several excerpts from the
recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in
this release was accessed February 8th, 2019. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
OVERSTOCK.COM, INC. (OSTK) REPORT OVERVIEW
Overstock's Recent Financial Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, Overstock reported revenue of $440.58MM vs
$424.01MM (up 3.91%) and analysts estimated basic earnings per
share -$1.55 vs -$0.03. For the twelve months ended December 31st,
2017 vs December 31st, 2016, Overstock reported revenue of
$1,744.76MM vs $1,799.96MM (down 3.07%) and analysts estimated
basic earnings per share -$4.28 vs $0.49. Analysts expect earnings
to be released on March 21st, 2019. The report will be for the
fiscal period ending December 31st, 2018. The reported EPS for the
same quarter last year was -$2.71. The estimated EPS forecast for
the next fiscal year is -$2.27 and is expected to report on March
21st, 2019.
To read the full Overstock.com, Inc. (OSTK) report, download it
here:
http://Capital-Review.com/register/?so=OSTK
-----------------------------------------
REGENERON PHARMACEUTICALS, INC. (REGN) REPORT
OVERVIEW
Regeneron Pharmaceuticals' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Regeneron Pharmaceuticals reported revenue
of $1,927.80MM vs $1,582.42MM (up 21.83%) and analysts estimated
basic earnings per share $7.58 vs $1.61 (up 370.81%). For the
twelve months ended December 31st, 2018 vs December 31st, 2017,
Regeneron Pharmaceuticals reported revenue of $6,710.80MM vs
$5,872.20MM (up 14.28%) and analysts estimated basic earnings per
share $22.65 vs $11.27 (up 100.98%). Analysts expect earnings to be
released on May 2nd, 2019. The report will be for the fiscal period
ending March 31st, 2019. Reported EPS for the same quarter last
year was $3.98. The estimated EPS forecast for the next fiscal year
is $21.11 and is expected to report on February 5th, 2020.
To read the full Regeneron Pharmaceuticals, Inc. (REGN) report,
download it here:
http://Capital-Review.com/register/?so=REGN
-----------------------------------------
MOLECULAR TEMPLATES INC. (MTEM) REPORT
OVERVIEW
Molecular Templates' Recent Financial
Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, Molecular Templates reported revenue of
$6.75MM vs $0.65MM (up 941.98%) and analysts estimated basic
earnings per share -$0.19 vs -$0.62. For the twelve months ended
December 31st, 2017 vs December 31st, 2016, Molecular Templates
reported revenue of $3.40MM vs $1.88MM (up 80.59%) and analysts
estimated basic earnings per share -$2.11 vs -$59.04. Analysts
expect earnings to be released on March 27th, 2019. The report will
be for the fiscal period ending December 31st, 2018. Reported EPS
for the same quarter last year was -$0.26. The estimated EPS
forecast for the next fiscal year is -$1.14 and is expected to
report on March 27th, 2019.
To read the full Molecular Templates Inc. (MTEM) report,
download it here:
http://Capital-Review.com/register/?so=MTEM
-----------------------------------------
THE ENSIGN GROUP, INC. (ENSG) REPORT
OVERVIEW
The Ensign Group's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, The Ensign Group reported revenue of
$537.78MM vs $487.71MM (up 10.27%) and basic earnings per share
$0.51 vs $0.21 (up 142.86%). For the twelve months ended December
31st, 2018 vs December 31st, 2017, The Ensign Group reported
revenue of $2,040.66MM vs $1,849.32MM (up 10.35%) and analysts
estimated basic earnings per share $1.78 vs $0.79 (up 125.32%).
Analysts expect earnings to be released on May 1st, 2019. The
report will be for the fiscal period ending March 31st, 2019. The
reported EPS for the same quarter last year was $0.43. The
estimated EPS forecast for the next fiscal year is $2.25 and is
expected to report on February 5th, 2020.
To read the full The Ensign Group, Inc. (ENSG) report, download
it here:
http://Capital-Review.com/register/?so=ENSG
-----------------------------------------
LIMONEIRA CO (LMNR) REPORT OVERVIEW
Limoneira's Recent Financial Performance
For the three months ended October 31st, 2018 vs
October 31st, 2017, Limoneira reported revenue of $14.71MM vs
$15.93MM (down 7.63%) and analysts estimated basic earnings per
share -$0.29 vs -$0.19. For the twelve months ended October 31st,
2018 vs October 31st, 2017, Limoneira reported revenue of $129.39MM
vs $121.31MM (up 6.66%) and analysts estimated basic earnings per
share $1.26 vs $0.42 (up 200.00%). Analysts expect earnings to be
released on March 14th, 2019. The report will be for the fiscal
period ending January 31st, 2019. The reported EPS for the same
quarter last year was -$0.09. The estimated EPS forecast for the
next fiscal year is $1.56 and is expected to report on January
13th, 2020.
To read the full Limoneira Co (LMNR) report, download it here:
http://Capital-Review.com/register/?so=LMNR
-----------------------------------------
PRIMO WATER CORPORATION (PRMW) REPORT
OVERVIEW
Primo Water's Recent Financial Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, Primo Water reported revenue of $81.77MM
vs $82.21MM (down 0.53%) and analysts estimated basic earnings per
share -$1.45 vs $0.15. For the twelve months ended December 31st,
2017 vs December 31st, 2016, Primo Water reported revenue of
$286.07MM vs $142.54MM (up 100.70%) and analysts estimated basic
earnings per share -$0.19 vs -$0.21. Analysts expect earnings to be
released on March 5th, 2019. The report will be for the fiscal
period ending December 31st, 2018. The reported EPS for the same
quarter last year was -$0.02. The estimated EPS forecast for the
next fiscal year is $0.49 and is expected to report on March 5th,
2019.
To read the full Primo Water Corporation (PRMW) report, download
it here:
http://Capital-Review.com/register/?so=PRMW
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Nicole Garrens, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Oct 2023 to Oct 2024